Recombinant PRAME nuclear receptor transcriptional regulator [PRAME/8558R]



Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. Prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis. This gene encodes an antigen that is preferentially expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. The encoded protein acts as a repressor of retinoic acid receptor, and likely confers a growth advantage to cancer cells via this function. Alternative splicing results in multiple transcript variants.

Product Properties & Targets

Species Reactivity
Cellular Localization
Nucleus. Chromosome. Cytoplasm. Golgi apparatus. Cell membrane
Gene Name
Positive Control
Human testis or melanoma.
Recombinant fragment (around aa100-509) of human PRAME protein (exact sequence is proprietary)
Alternate Names
Melanoma antigen preferentially expressed in tumors, Opa-interacting protein 4, Preferentially expressed antigen of melanoma, Cancer/testis antigen 130; CT130; MAPE; Melanoma antigen preferentially expressed in tumors; OIP 4; OIP-4; OIP4; OPA interacting protein 4; Opa interacting protein OIP4; OPA-interacting protein 4; PRAME; Preferentially expressed antigen in melanoma; Preferentially expressed antigen of melanoma; RP23-250F8.3

Database Links

Entrez Gene ID

Additional Information

Human Gene Symbol
Chromosome Location
Mol. Weight of Antigen


  • Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:21822215, PubMed:26138980). The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980). In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation (PubMed:21822215). Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis (PubMed:16179254).

Known Applications & Suggested Dilutions

  • Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95&degC followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.

Key References

  • Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199-208. doi:10.1016/s1074-7613(00)80426-4

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody is stable for 24 months. ,Non-hazardous. No MSDS required.


This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA at 1.0mg/ml.


There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.


There are no reviews yet.

Be the first to review “PRAME nuclear receptor transcriptional regulator”

Your email address will not be published. Required fields are marked *

Recombinant mouse monoclonal antibodies and recombinant rabbit monoclonals to support your research

Shop Primary Antibodies